Mostrar el registro sencillo del ítem
Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
dc.creator | Eleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I. | en |
dc.date.accessioned | 2023-01-31T07:37:17Z | |
dc.date.available | 2023-01-31T07:37:17Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1097/CJI.0000000000000365 | |
dc.identifier.issn | 15249557 | |
dc.identifier.uri | http://hdl.handle.net/11615/71340 | |
dc.description.abstract | Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Journal of Immunotherapy | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380d | |
dc.subject | hepatitis B surface antigen | en |
dc.subject | nivolumab | en |
dc.subject | recombinant hepatitis B vaccine | en |
dc.subject | hepatitis B antibody | en |
dc.subject | hepatitis B surface antigen | en |
dc.subject | hepatitis B vaccine | en |
dc.subject | nivolumab | en |
dc.subject | PDCD1 protein, human | en |
dc.subject | programmed death 1 receptor | en |
dc.subject | adult | en |
dc.subject | antigen blood level | en |
dc.subject | Article | en |
dc.subject | cancer immunotherapy | en |
dc.subject | case report | en |
dc.subject | clinical article | en |
dc.subject | disease predisposition | en |
dc.subject | drug tolerability | en |
dc.subject | electrochemiluminescence | en |
dc.subject | follow up | en |
dc.subject | hemodialysis patient | en |
dc.subject | hepatitis B | en |
dc.subject | human | en |
dc.subject | humoral immunity | en |
dc.subject | kidney hypoplasia | en |
dc.subject | lung metastasis | en |
dc.subject | lung nodule | en |
dc.subject | male | en |
dc.subject | memory cell | en |
dc.subject | middle aged | en |
dc.subject | nephrectomy | en |
dc.subject | plasma cell | en |
dc.subject | priority journal | en |
dc.subject | renal cell carcinoma | en |
dc.subject | treatment response | en |
dc.subject | vaccination | en |
dc.subject | hemodialysis | en |
dc.subject | hepatitis B | en |
dc.subject | humoral immunity | en |
dc.subject | immunology | en |
dc.subject | immunotherapy | en |
dc.subject | kidney tumor | en |
dc.subject | metabolism | en |
dc.subject | procedures | en |
dc.subject | Hepatitis B | en |
dc.subject | Hepatitis B Antibodies | en |
dc.subject | Hepatitis B Surface Antigens | en |
dc.subject | Hepatitis B Vaccines | en |
dc.subject | Humans | en |
dc.subject | Immune Checkpoint Inhibitors | en |
dc.subject | Immunity, Humoral | en |
dc.subject | Immunotherapy | en |
dc.subject | Kidney Neoplasms | en |
dc.subject | Male | en |
dc.subject | Memory B Cells | en |
dc.subject | Middle Aged | en |
dc.subject | Nivolumab | en |
dc.subject | Programmed Cell Death 1 Receptor | en |
dc.subject | Renal Dialysis | en |
dc.subject | Lippincott Williams and Wilkins | en |
dc.title | Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |